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Abstract
Background: Genomic techniques in recent years have allowed the identification of many mutated genes
important in the pathogenesis of acute myeloid leukemia (AML). Together with cytogenetic aberrations, these gene
mutations are powerful prognostic markers in AML and can be used to guide patient management, for example
selection of optimal post-remission therapy. The mutated genes also hold promise as therapeutic targets
themselves. We evaluated the applicability of a gene panel for the detection of AML mutations in a diagnostic
molecular pathology laboratory.
Methods: Fifty patient samples comprising 46 AML and 4 other myeloid neoplasms were accrued for the study.
They consisted of 19 males and 31 females at a median age of 60 years (range: 18–88 years). A total of 54 genes
(full coding exons of 15 genes and exonic hotspots of 39 genes) were targeted by 568 amplicons that ranged from
225 to 275 bp. The combined coverage was 141 kb in sequence length. Amplicon libraries were prepared by
TruSight myeloid sequencing panel (Illumina, CA) and paired-end sequencing runs were performed on a MiSeq
(Illumina) genome sequencer. Sequences obtained were analyzed by in-house bioinformatics pipeline, namely
BWA-MEM, Samtools, GATK, Pindel, Ensembl Variant Effect Predictor and a novel algorithm ITDseek.
Results: The mean count of sequencing reads obtained per sample was 3.81 million and the mean sequencing
depth was over 3000X. Seventy-seven mutations in 24 genes were detected in 37 of 50 samples (74 %). On
average, 2 mutations (range 1–5) were detected per positive sample. TP53 gene mutations were found in 3 out of 4
patients with complex and unfavorable cytogenetics. Comparing NGS results with that of conventional molecular
testing showed a concordance rate of 95.5 %. After further resolution and application of a novel bioinformatics
algorithm ITDseek to aid the detection of FLT3 internal tandem duplication (ITD), the concordance rate was revised
to 98.2 %.
Conclusions: Gene panel testing by NGS approach was applicable for sensitive and accurate detection of
actionable AML gene mutations in the clinical laboratory to individualize patient management. A novel algorithm
ITDseek was presented that improved the detection of FLT3-ITD of varying length, position and at low allelic
burden.
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Background
The molecular basis of AML is heterogeneous. Cytogen-
etic study is well documented as a mandatory test at
diagnosis to stratify patients into favorable, intermediate
and adverse prognostic categories [1]. The identification
of gene mutations in AML allows the further
characterization of the molecular heterogeneity of this
disease, especially with the subgroup of intermediate risk
AML that often exhibit a normal karyotype [2]. In the
recommendation by the European LeukemiaNet (ELN),
mutations involving three genes NPM1, FLT3 and
CEBPA are considered in AML prognostication scheme
[3]. Cytogenetically normal AML (CN-AML) with mu-
tated NPM1 without FLT3-ITD, or mutated CEBPA, are
incorporated in the favorable genetic group. Recent data
shows that only double, but not single, CEBPA muta-
tions confer a favorable prognosis [4–7]. Likewise the
National Comprehensive Cancer Network (NCCN)
Guideline for AML incorporates CN-AML with NPM1
mutation or isolated CEBPA mutation in the absence of
FLT3-ITD in the better-risk status category, whilst CN-
AML with FLT3-ITD mutation is considered poor-risk
[8]. The detection of concurrent KIT mutation relegates
the core binding factor (CBF)-related AML from better-
risk to intermediate-risk.
With the sequencing of the AML genome [9], the
first cancer genome to be sequenced, mutations in-
volving many more genes important in
leukemogenesis are being deciphered. Through the
whole genome sequencing approach, the genomic and
epigenomic landscapes of adult de novo AML [10]
and the clonal architecture of secondary AML [11]
are comprehensively described. The genetic aberra-
tions can be grouped under nine categories defined
according to biological function and a putative role in
AML pathogenesis, namely transcription factor fu-
sions, gene encoding nucleophosmin (NPM1), tumor
suppressor genes, DNA methylation-related genes
(DNMT3A, IDH1, IDH2 and TET2), activated signal-
ing genes, chromatin modifying genes, myeloid tran-
scription factor genes, cohesin complex genes and
spliceosome complex genes [10]. The clinical utility of
these AML gene mutations is under investigation [12,
13]. Besides serving as powerful prognostic indicators,
the mutational profile may have the potential to affect
treatment decision in AML. For example, patients in
the favorable genetic subgroup of mutated NPM1
lacking FLT3-ITD may be considered for post-
remission chemotherapy alone without resorting to
allogeneic bone marrow transplantation (BMT) [14],
and more recently the most favorable treatment re-
sponse is reported in mutated NPM1 lacking FLT3-
ITD and harboring IDH2 R140 mutation [15]. Regard-
ing upfront treatment, DNMT3A and NPM1
mutations together with MLL translocations, predict
for an improved outcome with high-dose daunorubi-
cin induction chemotherapy [15]. Moreover, mutations
of the DNA methylation genes may predict for re-
sponse to hypomethylation agents [16], although this
issue remains controversial [17]. Finally, these AML
gene mutations are themselves novel drug targets, as
evident by the clinical trials on the FLT3 inhibitors
[18] and IDH2 inhibitors [19].
It should be noted that whole genome sequencing and
whole exome sequencing are predominantly research
tools. To serve clinical management needs, accurate
genetic testing results should be reported with a reason-
able short turnaround time. We perform clinical evalu-
ation of a gene panel for testing myeloid disorders by




Fifty patient samples were accrued from April 2011 to
November 2014. They comprised 19 males and 31 fe-
males at a median age of 60 years (range 18–88 years).
The diagnoses were M0 = 1, M1 = 7, M2 = 12, M3 = 1,
M4 = 5, M5 = 3, M6 = 2, not otherwise specified (NOS)
= 4, AML with myelodysplasia (MDS) related changes
(AML-TMDS) = 5, AML transformed from MDS or
MDS/MPD = 3, therapy-related AML = 1, refractory
AML = 2, high-grade MDS = 3 and atypical chronic mye-
loid leukemia = 1. A diagnosis of AML-NOS was ren-
dered in four patients due to diagnosis on peripheral
blood only (n = 2), aparticulate bone marrow aspirate
(n = 1) and diagnosis at another institution (n = 1).
The study was approved by the Research Ethics Com-
mittee of Hong Kong Sanatorium & Hospital (refer-
ence number: REC-2015-02).
DNA was extracted from the corresponding speci-
mens (bone marrow = 42 and peripheral blood = 8)
using QIAamp DNA Blood Mini Kit (Qiagen,
Germany). Four additional samples were available
from 3 patients for comparison (buccal swab and
second peripheral blood samples of patient 31, post-
treatment sample of patient 35 and relapsed sample
of patient 36). Extracted DNA was quantified using
Qubit dsDNA BR Assay Kit and Qubit 2.0
Fluorometer (Life Technologies, USA).
Any known mutation status of FLT3, NPM1, KIT,
CALR, MPL, CSF3R by Sanger sequencing and JAK2
V617F by allele-specific polymerase chain reaction
(PCR) and PCR-restriction fragment length polymorph-
ism (PCR-RFLP) analysis of the patient samples were cu-
rated from the clinical record for comparison with NGS
results.
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Control samples
Archival DNA samples (n = 11) with known mutations
in CALR (n = 6), JAK2 (n = 2), KIT (n = 1), MYD88 (n =
1) and TP53 (n = 1) were retrieved as positive controls
to validate the NGS myeloid panel. DNA extracted from
peripheral blood samples of healthy adults with normal
complete blood profile (n = 18) were accrued in July and
October 2014 as negative controls. These control sam-
ples were analyzed in the same way as the patient
samples.
NGS myeloid gene panel
The myeloid gene panel targets 54 genes (full coding
exons of 15 genes: BCOR, BCORL1, CDKN2A,
CEBPA, CUX1, DNMT3A, ETV6/TEL, EZH2,
KDM6A, IKZF1, PHF6, RAD21, RUNX1/AML1,
STAG2 and ZRSR2, and exonic hotspots of 39 genes:
ABL1, ASXL1, ATRX, BRAF, CALR, CBL, CBLB,
CBLC, CSF3R, FBXW7, FLT3, GATA1, GATA2,
GNAS, HRAS, IDH1, IDH2, JAK2, JAK3, KIT, KRAS,
KMT2A/MLL, MPL, MYD88, NOTCH1, NPM1,
NRAS, PDGFRA, PTEN, PTPN11, SETBP1, SF3B1,
SMC1A, SMC3, SRSF2, TET2, TP53, U2AF1 and
WT1) by 568 amplicons (length range: 225–275 bp).
The combined coverage was 141 kb. Amplicon se-
quencing libraries were prepared from 50 ng of
DNA per sample using TruSight myeloid sequencing
panel (Illumina, USA). A highly multiplexed pool of
oligonucleotide pairs upstream and downstream to
each region of interest (ROI) was employed. Each
oligonucleotide contained unique target-specific se-
quences and universal adaptor sequence used in the
subsequent amplification reaction. For each sample,
an extension-ligation reaction extended across the
ROI and followed by ligation to unite the two probes
to yield a library of templates with common ends.
This library of new templates was PCR amplified
with a unique pair of indexes incorporated for
downstream sequence-based sample identification.
After PCR clean-up, double-stranded DNA length
and quantity of individual libraries were assessed by
DNA 1000 kit and 2100 Bioanalyzer system (Agilent,
USA). Libraries were normalized according to the
measured quantity and pooled in batches (8 to 24 li-
braries per pool). Paired-end sequencing runs were
performed on a MiSeq (Illumina, USA) with reagent
kit v3 according to manufacturer’s instructions.
Variant calling and annotation
Paired sequences obtained from each sample were
mapped to human genome reference GRCh37/hg19
using BWA-MEM [20] version 0.7.7 with default param-
eters. Three variant callers were used: (1) Samtools [21]
version 0.1.19, with mpileup command parameters -L
100000 -d 100000 to cater for amplicons with depth ex-
ceeding 250-fold and bcftools command parameter-
m0.99 to use the new insertion-deletion (INDEL) calling
model; (2) GATK HaplotypeCaller [22] version 2.8-1 ac-
cording to the best practices recommended by the au-
thors; and (3) VarScan [23] version 2.3.7 somatic
mutation calling mode based on one of the negative
controls or the matched germline DNA if available. For
detection of FLT3 internal tandem duplication (ITD),
additional variant callers were used specifically for the
region chr13:28607161–28609590: (1) Pindel [24] ver-
sion 0.2.5a7 with the insert size configured as the sum-
mation of forward and reverse sequencing read length,
to adapt the algorithm to the amplicon sequencing reads
in this study, and (2) a novel algorithm ITDseek devel-
oped in this study (details described in a separate
section).
Variant calls were first annotated by Ensembl Variant
Effect [25] Predictor version 75 and then manually ex-
amined by at least two individuals. Sequence alignment
of selected variants was manually examined with Inte-
grative Genomics Viewer [26] (IGV). ROI sequencing
depth was summarized using BEDTools [27] version
2.19.1 Minimum reportable variant allele frequency (AF)
is 10 % of sequencing depth at least 500-fold. ROI with
depth less than 500-fold were regarded as sub-optimal
regions. Variants found to be reported in COSMIC data-
base version 67 and/or dbSNP version 138 were priori-
tized for manual examination while those reported in
1000 Genomes project (phase 1) were excluded. FLT3
ITD and ASXL1 c.1934dupG mutations were confirmed
in selected patients using PCR fragment analysis by ca-
pillary electrophoresis (primer sequences available upon
request) and analysis software Peak Scanner version 1.0
(http://www.appliedbiosystems.com). Variants were de-
scribed according to the recommendations of Human
Genome Variation Society (HGVS). Variant descriptions
were checked by Mutalyzer Name Checker (http://
mutalyzer.nl).
Evaluation of FLT3 ITD detection algorithms and
development of a novel detection algorithm ITDseek
FLT3 ITD detection performance of Pindel, Samtools,
GATK HaplotypeCaller were compared based on a sim-
ulated dataset of ITD mutations. An in silico FLT3 ITD
sequencing read simulator ITDsim was developed based
on BioPerl [28]. The amplicon targeting
chr13:28,608,112–28,608,312 (both primer binding sites
excluded) was chosen as the simulation target due to its
highest reported FLT3 mutation rate in COSMIC among
the three amplicons in the region. All combinations (n =
40,401) of ITD lengths (range: 1–201 bp; n = 201) and
starting positions (chr13:28,608,112–28,608,312; n = 201)
were simulated separately. ITD allelic burden was
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defined as 50 %. For each combination, 1000 paired-end
ITD reads and 1000 paired-end wild-type reads (both
2 × 275 bp) were simulated and the FASTQ file pair was
subject to variant calling as described above. Simulation
and corresponding variant calling were performed on a
Cray XC30 supercomputer.
To overcome the difficulty in calling long ITD muta-
tions with short-read NGS amplicon sequencing, a novel
FLT3 ITD detection algorithm ITDseek was developed
based on the following principles. It takes SAM/BAM
alignments as input and outputs any detected ITD muta-
tions in VCF format. In case of a short ITD (e.g., 9 bp)
present in the middle of raw sequencing reads (e.g.,
250 bp), the wild-type sequences upstream and down-
stream of ITD mutation are long enough for proper align-
ment to the FLT3 locus, with an insertion in between
representing the additional sequence (operation “I” in
CIGAR field of SAM alignment output by BWA-MEM).
General-purpose variant callers like Samtools, GATK
HaplotypeCaller and VarScan could then readily identify
the inserted nucleotides. In contrast, if a given ITD is too
long and/or too close to either end of amplicon, the se-
quence downstream of ITD mutation will become too
short or even completely absent in the raw sequences
obtained. Without long enough downstream se-
quences, the additional duplicated nucleotides are
marked as soft-clipped instead (operation “S” in
CIGAR field). These soft-clipped nucleotides are usu-
ally ignored by general-purpose variant callers as if
they are sequencing adapter. In principle, realignment
of soft-clipped nucleotides is a way to identify pos-
sible ITD mutations. Since BWA-MEM outputs a sep-
arate secondary alignment representing those soft-
clipped nucleotides, such realignment is effectively
performed. However, secondary alignments are usually
ignored by general-purpose variant callers. ITDseek
specifically searches for any soft-clipping points in
primary alignments and correlate them with any cor-
responding secondary alignments for ITD identifica-
tion. The length of ITD was extrapolated by the
distance between the point of soft-clipping and the
beginning of realignment of soft-clipped bases. The
analysis is performed in individual reads and direc-
tions separately to identify any rare ITD clone (as
rare as a single read only) or multiple ITD clones. In
case of a special FLT3 ITD type that the additional
sequence is entirely insertion of unknown origin,
there is no secondary alignment. ITDseek identifies
such ITD by comparing points of soft-clipping in se-
quencing read pairs. ITDseek was also evaluated
based on the same simulated dataset described before.
Source codes and documentation of ITDsim and ITDseek
are available at http://github.com/tommyau/ITDseek for
non-commercial use.
Results
High concordance of NGS results versus known mutations
status
The NGS panel showed 100 % concordance in detecting
all 5 single-nucleotide mutations and 6 INDEL muta-
tions from 11 corresponding positive control samples.
The single-nucleotide mutations were JAK2 c.1849G > T
p.Val617Phe (n = 2), KIT c.2447A > T p.Asp816Val,
MYD88 c.794 T > C p.Leu265Pro and TP53 c.916C > T
p.Arg306* (all n = 1). The INDEL mutations included in-
sertions of 5 bp (CALR c.1153_1154insCTTGT,
c.1154_1155insTTGTC) and deletions of 19 bp (CALR
c.1124_1142del), 34 bp (CALR c.1103_1136del) and
52 bp (CALR c.1099_1150del; n = 2). No mutation was
detected from all 18 negative control samples.
Next, we compared NGS results with known mutation
status of 42 patient samples from conventional testing
(n = 111 results, both positive and negative), including
FLT3 ITD (n = 39), FLT3 tyrosine kinase domain (TKD;
n = 39), NPM1 (n = 22), JAK2 (n = 4), KIT (n = 4), CALR,
MPL and CSF3R (all n = 1). The concordance rate was
95.5 % (106 of 111), being observed in 17 mutation posi-
tive results (NPM1 n = 8, FLT3 TKD n = 5, FLT3 ITD n
= 3, KIT n = 1) and 89 mutation negative results (FLT3
TKD n = 34, FLT3 ITD n = 32, NPM1 n = 14, JAK2 and
KIT both n = 3, CALR, CSF3R and MPL all n = 1). The 5
discrepancies were JAK2 V617F (n = 1) and FLT3 ITD
(n = 4) mutations missed by NGS as elaborated below.
For patient 31, both allele-specific PCR and PCR-RFLP
analysis of the initial sample (July 2014) showed JAK2
V617F weakly positive result (Fig. 1). No such mutation
was reported by the NGS panel on the same sample. We
asked whether the mutation was actually detected by
Fig. 1 JAK2 V617F allele frequencies as measured by next-generation
sequencing. Samples included 18 negative controls (NC) and 3 sam-
ples of patient 31, namely buccal swab (BS) and peripheral blood
(PB) samples in July 2014, and peripheral blood sample in
October 2014.
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NGS but not reported based on the reportable minimum
variant AF (10 %). To obtain the AF of JAK2 V617 re-
gardless of variant callers, we checked aligned reads at
the corresponding genomic position chr9:5073770G > T.
V617F AF was 4.1 % in the initial sample, 0.9 % in
matched buccal swab sample and 25.6 % in the second
peripheral blood sample (October 2014) (Fig. 1). The
mean noise level was 0.6 % based on 18 negative con-
trols (0.2–1.3 %, 99 % confidence interval 0.45–0.79 %;
Fig. 1). The slight but significant elevation of JAK2
V617F AF in the initial sample showed the mutation was
indeed detectable by NGS and confirmed the weakly
positive results by conventional molecular analysis.
Known FLT3 ITD mutations detected by Sanger se-
quencing in patients 3, 36, 37 and 41 were originally not
reported by the NGS panel. However, lengths of the ITD
mutations (30–189 bp, n = 4) fell within the range re-
ported to be detectable by Pindel (17–185 bp) [29],
which was one of the variant callers used in this study.
In the study by Spencer et al. employed sonication-based
DNA fragmentation during sequencing library prepar-
ation, start positions of aligned reads were randomly dis-
tributed [29]. In contrast, start positions of aligned reads
in this study were fixed by primers of corresponding
PCR amplicons. We hypothesized that the ITD detection
sensitivity also depended on the relative positions of
ITD within corresponding amplicons.
Comprehensive bioinformatics evaluation of FLT3 ITD
detection methods
We evaluated the performance of variant callers for ITD
detection when the mutation position varied along the
amplicon. A simulation approach was chosen to encom-
pass a wide range of possible ITD mutations regardless
of actual sample availability. A read simulator ITDsim
was developed to simulate 2 × 275 bp sequencing data
for ITD mutations at various starting positions, based on
the amplicon with highest reported FLT3 ITD mutation
rate (chr13:28,608,112–28,608,312) in the region. Given
that the length of amplified region was 201 bp, starting
positions included all these 201 positions and mutation
length ranged from 1 to 201 bp (total 40401 combina-
tions). For each combination of starting position and
length, a pair of FASTQ files was simulated with sequen-
cing depth 2000X and ITD AF 50 %. To determine the
best possible performance of ITD detection, the simu-
lated FLT3 sequencing reads were perfect-matching se-
quences derived from the GRCh37/hg19 reference
genome without errors and all other amplicons were not
simulated. Bioinformatics analysis of the simulated data
was performed in the same way as the clinical samples.
Pindel, GATK HaplotypeCaller and Samtools detected
58.9, 45.5 and 23.0 % of simulated ITD mutations, re-
spectively (Fig. 2a). Although Pindel detected most ITD
mutations among the three callers, the maximum length
of detected ITD mutation decreased from 201 bp to
45 bp at the 41st nucleotide and 201st nucleotide of the
amplicon, respectively (Fig. 2a). ITD detection sensitivity
was demonstrated to depend on not only length but also
its relative position in the amplicon.
A novel FLT3 ITD detection algorithm ITDseek
We therefore closely examined the BWA-MEM align-
ments and observed two major differences between
wild-type and ITD sequencing reads: (1) longer se-
quences became soft-clipped (ignored for analysis in-
cluding variant calling), compared with consistently
short soft-clipped sequences representing universal
adapters, and (2) there was additional alignment of part
of the soft-clipped sequences to the same FLT3 locus,
but marked as supplementary alignment that was ig-
nored for analysis in a similar manner as soft-clipping.
Based on these observations, a novel ITD mutation algo-
rithm ITDseek was developed and detected 73.1 % of
the simulated ITD mutations (Fig. 2a). For most starting
positions in the amplicon (1 to 198), although the mini-
mum length of detected ITD mutation ranged from 15
to 83 bp, the maximum detection length was consist-
ently 201 bp (the longest simulated length). ITDseek
was insensitive to the remaining 3 starting positions
(199–201 bp).
More importantly, ITDseek detected 96.8 % (10152 of
10491) of combined false negatives by the other three
callers (Fig. 2b). ITDseek increased overall detection rate
from 74.0 % (other three callers) to 99.2 % (all four cal-
lers). Computation requirement of ITDseek was minimal
that it took <20 s and <2GB RAM to analyze a full
MiSeq V3 run of 8 samples by 8 CPU cores (5-year-old
Intel Xeon 2.8GHz processors).
After including ITDseek as an additional variant caller,
known FLT3 ITD mutations of patients 3 (189 bp), 37
(30 bp) and 41 (30 bp) were detected to resolve 3 dis-
crepancies. Regarding the remaining patient 36, ITDseek
detected two different ITD mutations of lower AF (63
and 54 bp) but not the known 75 bp ITD mutation. A
3 bp deletion c.1739_1741delAGG located near the ex-
tension/ligation oligo binding site of amplicon 2 was also
detected by the NGS panel (Fig. 3a). Reanalysis of ori-
ginal Sanger sequences confirmed the 3 bp deletion and
suggested that it was in cis with 75 bp ITD mutation.
Sanger sequencing of relapsed sample showed that the
two in cis mutations became almost the only FLT3 allele
detected. NGS of that relapsed sample detected the 3 bp
deletion at VAF 99.9 %. NGS sequencing depth of ampli-
con 2 dropped from 5500X (initial sample) to 70X (re-
lapsed sample), which was consistent with complete
drop-out of the ITD allele (Fig. 3a). PCR fragment
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analysis of the original and relapsed samples supported
these observations (Fig. 3b).
In patient 20, which was reported ITD negative by
Sanger sequencing, ITDseek detected two ITD muta-
tions (119 and 25 bp). PCR fragment analysis confirmed
both mutations (Fig. 3b). The allelic burden (1.4 and
3.2 %, respectively) was below the detection limit of
Sanger sequencing. Taken together, after further reso-
lution and application of ITDseek, there were still 2
samples (patients 20 and 36) with discrepancies and
Fig. 2 FLT3 ITD detection performance of a novel algorithm ITDseek versus Pindel, GATK HaplotypeCaller and Samtools. a Detected combination
of ITD length and relative position in the FLT3 NGS amplicon 2 (chr13:28,608,112-28,608,312) was indicated by red shading in the corresponding
panel of each caller. b Venn diagram showing the number of ITD alleles detected by any or none of the four tested callers.
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concordance was 98.2 % (109 of 111). FLT3 mutation de-
tection was more sensitive by NGS since ITDseek de-
tected 2 additional ITD alleles with low VAF in both
patients 20 and 36, notwithstanding the one complex al-
lele in patient 36 that was undetected by NGS due to al-
lele drop-out.
NGS mutation profile
The mean count of sequencing reads obtained per sam-
ple was 3.81 million (range 2.02–8.51 million) and the
mean sequencing depth was over 3000X. Seventy-seven
mutations in 24 genes (Table 1) were detected in 37 of
50 patient samples (74 %). On average 2 mutations
(range 1–5) were detected per positive sample. Muta-
tions were detected in the following genes: FLT3 (n =
16), NPM1 (n = 12), IDH2 (n = 7), ASXL1, DNMT3A,
TET2, TP53 (all n = 4), CEBPA, IDH1 (both n = 3),
CSF3R, KIT, RAD21, SMC3, STAG2 (all n = 2), CBL,
ETV6, EZH2, IKZF1, JAK2, NRAS, PTPN11, SETBP1,
SF3B1 and ZRSR2 (all n = 1). The two most frequently
mutated genes in our patient cohort, FLT3 and NPM1,
were in keeping with the mutational frequency of genes
in AML as reported in the literature (Fig. 4) [30]. Based
on mechanism of action, genes involved in signal trans-
duction (FLT3, CSF3R, KIT, NRAS, PTPN11, CBL and
JAK2) and DNA methylation (DNMT3A, TET2, IDH1
and IDH2) were the most frequent mutated groups, ac-
counting for 24 (31 %) and 18 (23 %) out of 77 detect-
able mutations [31].
The small patient number in our cohort precluded
meaningful correlation between gene mutations with
clinical features and outcome or survival analysis. This
Fig. 3 FLT3 of patients 36 and 20 as characterized by next-generation sequencing and fragment analysis. a NGS sequencing depth histogram for
3 amplicons covering FLT3 exons 13 to 15 at scale 0–30000X. Magnitude of drops in sequencing depth at amplicon 2 and the region of 3 bp
deletion (c.1739_1741delAGG; indicated by arrow) was proportional to the deletion VAF as indicated. The amplicon 2 covered the 75 bp ITD
(indicated by triangle) but was affected by the 3 bp deletion in cis. b PCR fragment analysis for FLT3 ITD detection. ITD of 54 bp, 63 bp (patient
36 initial sample), 25 bp and 119 bp (patient 20) detected by NGS and ITDseek were confirmed by the corresponding fragments. Single additional
fragment detected in both initial and relapsed samples of patient 36 confirmed the additional allele, which consisted of 75 bp ITD and 3 bp
deletion in cis and was not detected by NGS due to allele drop-out.
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Table 1 Summary of 50 patients in this study.
No. Sex/
Age
Diagnosis Cytogenetics Conventional molecular testing NGS myeloid panel Clinical outcome
1 M/56 AML-NOS* Not done FLT3- KIT p.D816V Alive on treatment
2 F/37 M1 Near-
tetraploid and
complex
NPM-, FLT3- TP53 p.E62* Treated in Mainland China
3 M/60 High grade
MDS
Normal FLT3-ITD (189 bp), del(5q) FISH- FLT3 ITD (189 bp) Alive in CR after BMT
4 F/83 M6 No growth FLT3-ITD-TKD+ FLT3 p.D835Y Died




NPM1-, FLT3- Negative Died after BMT
6 M/57 AML-TMDS Normal NPM1-, FLT3- DNMT3A p.E423* Died of relapse after BMT
IDH2 p.R140Q
STAG2 p.R259*




Not done FLT3- SF3B1 p.K666E Died
9 F/35 M2 inv(16) KIT+ KIT p.D816V Alive in CR after BMT
10 F/44 M4 Normal NPM+, FLT3- NPM1 p.W288Cfs*12 Alive in CR
11 F/82 M5a No growth FLT3- Negative Died




No growth FLT3-, del(5q) FISH-, BCR-ABL1- Negative Died




15 M/82 M1 add(3q),
add(7q), +8,
FLT3-, BCR-ABL- Negative Died
16 F/59 M6 Poor growth NPM1+, FLT3- NPM1 p.W288Cfs*12 Died
ETV6 p.Y346*
IDH2 p.R140W









19 F/64 AML-NOSb Normal NPM1+, FLT3 ITD-TKD+ NPM1 p.W288Cfs*12 Died
FLT3 p.D835Y
DNMT3A p.W313*
SMC3 c.3105 + 2 T > C
RAD21 p.Q132*
20 M/54 M1 Normal NPM1+, FLT3- NPM1 p.W288Cfs*12 Alive in CR
IDH1 p.R132H
FLT3 ITD (25 bp)
FLT3 ITD (119 bp)
21 M/44 M1 Constitutional
inv(9)
FLT3-, BCR-ABL- Negative Died. History of HD treated by
BEACOPP
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Table 1 Summary of 50 patients in this study. (Continued)
22 F/44 M2 Not done FLT3 ITD + TKD- NPM1 p.W288Cfs*12 Died
RAD21 c.1161 + 2 T > A
FLT3 ITD (72 bp)
23 F/33 M2 therapy-
related
Poor growth NPM1-, FLT3- Negative Died. History of treated breast
cancer
24 F/26 M3 No growth PML-RARA(s)+, FLT3 ITD + TKD- FLT3 ITD (33 bp) Alive in CR
25 M/65 M5a +8 NPM1-, FLT3 ITD + TKD- FLT3 ITD (54 bp) Died
26 F/74 M0 +22 CBFB-MYH11- NPM1- FLT3- BCR-ABL1- Negative Alive in CR and maintained on
monthly vidaza
27 F/77 AML-TMDS +8 Not done Negative Lost to follow up. History of lung
cancer
28 M/18 M2 t(8;21),-Y AML1-ETO+, KIT-, NPM1-, FLT3- Negative Alive in CR
29 F/61 AML-NOSa Poor growth NPM1-, FLT3 ITD-TKD+, BCR-ABL-, AML1-
ETO-
FLT3 p.D835Y Alive in CR
30 F/39 M2 +8 AML1-ETO-, NPM+, FLT3- NPM1 p.W288Cfs*12 Alive in CR
NRAS p.G12D
31 M/70 M1 Normal NPM-, FLT3-, PDGFRB FISH-, FIP1L1-
PDGFRA-, BCR-ABL-,
TET2 p.S1848* NR to vidaza. Further treatment in
Mainland China
TET2 p.G1152E
JAK2 V617F weak+ JAK2 p.V617F (VAF 4.1 %,
below original reportable
threshold)




33 F/68 M4 Normal FLT3- NPM1 p.W288Cfs*12 Difficult CR and on vidaza
TET2 p.L346Rfs*2
34 F/24 M2 t(8;21) AML1-ETO+, BCR-ABL-, PML-RARA-,
NPM1-, FLT3-
Negative Alive in CR
35 M/60 M5a +8 Not done NPM1 p.W288Cfs*12 Alive on treatment
PTPN11 p.G503A
ASXL1 p.G646Wfs*12
36 F/62 M1 Normal AML1-ETO-, BCR-ABL1-, PML-RARA-, NPM1
+, FLT3 ITD+ in cis with 3 bp deletion
(c.1739_1741delAGG)




FLT3 ITD (54 bp)
FLT3 ITD (63 bp)
IDH2 p.R140Q
37 F/46 M4 Near-
tetraploid
AML-ETO-, BCR-ABL1-, FLT3 p.D835Y Responded to sorafenib and HHT.
Received BMT from sibling donor
and on treatmentFLT3 ITD+ (30 bp), FLT3 TKD+ FLT3 ITD (30 bp)
38 M/66 AML-TMDS Complex > 3
abnormalities












Normal NPM1+, FLT3-, MLL FISH- NPM1 p.W288Cfs*12 Died
CBL c.1096-1G > T
41 F/78 AML-TMDS add(21q) FLT3 ITD + TKD- FLT3 ITD (30 bp) Died
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notwithstanding, TP53 mutations were found in three
out of four patients (75 %) with complex and unfavor-
able cytogenetics. The mutational spectrum of the cyto-
genetic unfavorable group was rather different from that
of the cytogenetic normal or intermediate group in our
patient cohort. Interestingly, both ASXL1 p.G646Wfs*12
and NPM1 p.W288Cfs*12 mutations were detected in
the initial sample of patient 35 but not detected in the
post-treatment sample. Although whether the two muta-
tions occurred in the same or independent clones is un-
known, they represented one of the first documented
exceptions to mutual exclusion nature of ASXL1 and
NPM1 mutations in AML [32].
Discussion
While infrequent in CN-AML, mutations affected TP53
is associated with a complex karyotype [33], as con-
firmed by our patient cohort. This may define a distinct
subgroup of AML that displays primary resistance to
therapy and a very dismal prognosis [34, 35]. It is un-
clear whether TP53 mutations cause and promote in-
creasing cytogenetic instability, or whether these are
secondary mutations occurring after the onset of
chromosomal instability. One study showed that a subset
of patients with complex karyotype did not have TP53
mutations, whilst all TP53-mutated AML were found in
complex karyotype, suggesting that complex karyotype
preceded TP53 mutations [36]. Also most mutations of
TP53 were associated with del(17p) [36], supporting the
contention that TP53 mutations were the second hit in
leukemogenesis. More recently, TP53 mutations associ-
ated with therapy-related AML were shown to be
present before the exposure to chemotherapy, suggesting
that a pre-leukemic clone harboring TP53 mutation
gained survival advantage after chemotherapy, rather
than induced by chemotherapy [37]. Hence TP53-
mutated AML and therapy-related AML may have more
in common than previously recognized.
Detection of FLT3 ITD is an important test for CN-
AML due to its impact on prognosis and treatment
[38]. Highly variable length, allelic burden and num-
ber of the ITD mutations were observed [39]. These
characteristics pose a challenge in detection by next-
generation sequencing, specifically not the sequencing
process per se, but the bioinformatic analysis of the
short sequences obtained (<300 bp). Pindel was
shown to be the state-of-the-art ITD variant caller,
particularly its detection of ITD alleles with length up
to 185 bp [29]. However, our study showed that Pin-
del detected 3 ITD alleles of length 33 bp (patient
24) to 72 bp (patient 22) but not 4 ITD alleles of
length 30 to 189 bp. Similarly, a recent study showed
that Pindel detected 14 ITD alleles of length up to
approximately 60 bp but not 3 ITD alleles of length
approximately 50, 90 and 110 bp [40].
By comprehensive evaluation based on 40401 simu-
lated ITD alleles with length up to 201 bp, we demon-
strated that detection from amplicon-based NGS data
was dependent on relative ITD position within amplicon,
in addition to ITD length. Other laboratories may also
Table 1 Summary of 50 patients in this study. (Continued)
42 M/88 AML-NOS* Not done Not done IDH2 p.R140Q Alive on palliative care
43 M/63 M2 Normal Not done IDH2 p.R172K Alive on vidaza




Normal 5/7/del(20q) FISH-, BCR-ABL-, FLT3-, JAK2
V617F/CALR/MPL-
DNMT3A c.855 + 1G > T Alive on treatment
NPM1 p.W288Cfs*12
IDH2 p.R140Q
45 F/28 M4Eo inv(16) CBFB FISH+, CBFB-MYH11 PCR+ Negative Alive in CR
46 F/84 M4Eo Not done CBFB-MYH11 PCR+, FLT3-, NPM1-, KIT- Negative Died
47 M/51 Atypical
CML
Normal CSF3R-, BCR-ABL-, JAK2 V617F-, PDGFRB
FISH-, PDGFRA FISH-




48 F/53 M2 t(8;21) KIT- SMC3 p.S674_R675insL Alive in CR
49 M/65 High-grade
MDS
Normal Not done ASXL1 p.G646Wfs*12 Alive on vidaza + eltrombopag trial
50 M/51 M2 Normal NPM1-, FLT3-, AML1-ETO- CEBPA p.R343Afs*79 Alive on treatment
CEBPA p.K313dup
CR complete remission, NR non-remission, FISH fluorescence in-situ hybridization, vidaza 5-azacytadine, HHT homoharringtonine, HD Hodgkin lymphoma,
PML-RARA(s) short isoform of fusion transcript from PML bcr3 breakpoint, VAF variant allele frequency, FLT3 testing included detection of both ITD and TKD
*Diagnosis on PB only
aAparticulate aspirate and diagnosis by immunophenotyping only
bDiagnosis in another hospital
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use the simulator ITDsim to evaluate the performance
of their own bioinformatics pipeline. We also developed
a novel detection algorithm ITDseek because recently
developed tools including BreaKmer [41] and Genomon
ITDetector [42] were developed for sequencing library
prepared with random DNA fragmentation and similar
to Pindel. Amplicon Indel Hunter [43] was developed
for amplicon-based sequencing data but the actual im-
plementation was not available for parallel evaluation.
ITDseek detected most false negatives (97 % of simu-
lated samples) of Pindel, GATK and Samtools. For the
actual samples in this study, ITDseek detected ITD al-
leles up to 189 bp missed by Pindel. ITDseek was de-
signed to process the de facto standard BAM alignment
file with minimal computation time (<20 s for a whole
MiSeq run by 8 CPU cores) and is expected to be easily
incorporated in various bioinformatics pipelines of other
laboratories.
Conclusions
We show that gene panel testing by NGS approach in
a diagnostic molecular pathology laboratory allows
sensitive and accurate detection of actionable AML
gene mutations to individualize patient management.
The diagnostic approach to AML is facing a paradigm
shift in the genomics era [44]. As more targeted ther-
apy become available, the greater is the clinical de-
mand for comprehensive molecular profiling. The
results of genomic study hold promise for better un-
derstanding disease pathogenesis and classification, re-
fining prognostic stratification and uncovering new
drug targets. Further studies should focus on the
clinical utility of the genomics to document whether
this approach translated into improvements in AML
patient outcome and survival [45]. The novel algo-
rithm ITDseek presented in this paper improves the
detection of FLT3-ITD in the laboratory setting of
amplicon-based next-generation sequencing.
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